Principia Pharmaceuticals

Principia Biopharma is a late-stage biopharmaceutical company focused on developing transformative oral therapies for patients with immune-mediated diseases and oncology. Utilizing its proprietary Tailored Covalency platform, the company designs highly selective small molecule inhibitors that form either reversible or irreversible covalent bonds with their targets, aiming for the potency of biologics with the convenience of oral dosing. The company's lead assets include tolebrutinib (SAR442168), a brain-penetrant BTK inhibitor for multiple sclerosis, and rilzabrutinib, an oral BTK inhibitor for pemphigus and immune thrombocytopenia. In September 2020, Principia was acquired by Sanofi for approximately $3.68 billion to bolster Sanofi's immunology and inflammation pipeline.